drug

Berberine

berberine
MeSH D001599
as of 2026-07-01
Add to landscapeMonitor thisCompare thisAsk about this
at a glance
small molecule
Pre-approval / investigational in the US
Developed by Tianjin Anding Hospital
7 trials in the graph
Synthesized from structured facts only — each point cited above.

Mechanism & identity

Modality
small molecule

Indications

Trials

7
Berberine Improving Cognitive Impairments in Schizophrenia
NCT07359209—Completed
Berberine in Treating Negative Symptoms of Schizophrenia: Clinical Efficacy and Mechanisms
NCT07356765—Enrolling By Invitation
Comparison of Berberine and Metformin for the Treatment for MS in Schizophrenia Patients
NCT03708549Phase 4Unknown
Berberine as Adjuvant Treatment for Schizophrenia Patients
NCT02983188Phase 2, Phase 3Completed
Berberine Treat Metabolic Syndrome in Schizophrenia
NCT03251716—Completed
Berberine Effects on Clinical Symptoms and Metabolic Disturbance in Patients With Schizophrenia
NCT03548155—Completed
Berberine Effect on Cytokine, CRP, Metabolic Disturbance as an Adjunctive Therapy in Schizophrenia Patients
NCT02936414—Completed

KOLs & investigators

1
Zhang-Jin ZHANG, MMed, PhD

Facts & assertions

0 sourced
No assertions recorded for this entity.
relationships
The graph out of here
developer
Tianjin Anding Hospital
company
trial
Berberine Improving Cognitive Impairments in Schizophrenia
NA
trial
Berberine in Treating Negative Symptoms of Schizophrenia: Clinical Efficacy and Mechanisms
NA
trial
Comparison of Berberine and Metformin for the Treatment for MS in Schizophrenia Patients
PHASE4
trial
Berberine as Adjuvant Treatment for Schizophrenia Patients
PHASE2, PHASE3
trial
Berberine Treat Metabolic Syndrome in Schizophrenia
NA
trial
indication
Neurobehavioral Manifestations
indication
Schizophrenia
indication
Therapeutics
indication
Schizophrenia Spectrum and Other Psychotic Disorders
indication
KOL
Zhang-Jin ZHANG, MMed, PhD
KOL score —
person